

February 4, 2026

Dear Colleagues,

The Oregon State Public Health Laboratory (OSPHL) is pleased to inform you that our laboratory will resume pyrazinamide (PZA) testing on the BD BACTEC MGIT™ 960 platform beginning February 5, 2026. Please share this notice with your colleagues who may need this information.

Will OSPHL be able to continue testing for PZA susceptibility?

OSPHL currently has sufficient testing supplies and has not received notification of supply shortages from the manufacturer. At this time, we anticipate that testing will continue at OSPHL.

Resulting for Isolates Already Sent to CDC

Some isolates have already been sent to the Centers for Disease Control and Prevention (CDC) Laboratory for pncA gene sequencing. Your organization may continue to receive these results from OSPHL until all isolates in queue have been tested by the CDC Laboratory.

What caused the PZA testing pause at OSPHL?

In August 2024, OSPHL notified clients and colleagues that Becton, Dickinson and Company (BD) released a recall notice affecting the MGIT™ pyrazinamide (PZA) Kit used by OSPHL for drug susceptibility testing. OSPHL resumed testing in March 2025. A subsequent recall in May 2025 resulted in a second testing interruption.

(continues on next page)

Thank you for your partnership during these necessary testing interruptions. Please contact our laboratory team with questions at 503-693-4100 or:

- Mackenzie Clary, Tuberculosis Testing Lead,
mackenzie.clary@oha.oregon.gov
- Matthew Burns, General Microbiology Section Manager,
matthew.c.burns@oha.oregon.gov

Sincerely,

Patrick Luedtke, MD, MPH
Medical Director, OSPHL

Matthew Burns, MSc
General Microbiology Manager, OSPHL